Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - genexol is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer; in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - genexol is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - genexol is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer(nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - genexol is indicated for: primary treatment of ovarian cancer in combination with a platinum agent.; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

India - English - Central Drugs Standard Control Organization

lupin - paclitaxel - pm - 100mg - 1 vial

India - English - Central Drugs Standard Control Organization

lupin - paclitaxel - pm - 30mg - 1 vial

Egypt - English - EDA (Egyptian Drug Authority)

egyptian promotion center - infusion - 6 mg/ml

Egypt - English - EDA (Egyptian Drug Authority)

egyptian promotion center - infusion - 6 mg/ml

Singapore - English - HSA (Health Sciences Authority)

emerging pharma (s) pte ltd - paclitaxel - injection - 6 mg/ml - paclitaxel 6 mg/ml

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacorp (pty) ltd - injection - see ingredients - each 5,0 ml vial contains paclitaxel 100,0 mg